Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome

BACKGROUND: Hepatorenal syndrome is a potentially reversible renal failure associated with severe liver disease. The disease is relatively common among people with decompensated cirrhosis. Terlipressin is a drug that increases the blood flow to the kidneys by constricting blood vessels. The previous...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cochrane Database Syst Rev
Prif Awduron: Allegretti, Andrew S, Israelsen, Mads, Krag, Aleksander, Jovani, Manol, Goldin, Alison H, Schulman, Allison R, Winter, Rachel W, Gluud, Lise Lotte
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley & Sons, Ltd 2017
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6481608/
https://ncbi.nlm.nih.gov/pubmed/29943803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD005162.pub4
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg